Precision Medicine in Neurodegenerative Disorders: Part I: Volume 192 | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B13=Alberto J. Espay
Category1=Non-Fiction
Category=MBGR
Category=MFGM
Category=MJG
Category=MJN
Category=PSAN
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=In stock
Price_€100 and above
PS=Active
softlaunch

Precision Medicine in Neurodegenerative Disorders: Part I: Volume 192

English

Precision Medicine in Neurodegenerative Disorders, Part One, Volume 192 in the Handbook of Clinical Neurology deals with the Why in the approach to slow the progression of accelerated brain aging. This volume is intended to provide a scholarly background on the framework, basic science and conceptual pitfalls related to disease-modifying efforts in Parkinson's, Alzheimer's and other neurodegenerative disorders. Among topics covered are different models of precision medicine, the lumping-versus-splitting tension in biomarker development and therapeutics, and the rationale for replacing the convergence of the prevailing autopsy-based nosology of neurodegenerative diseases with the divergence of a systems biology approach to human diseases. Specific chapters are dedicated to the promise of genetic subtypes and the lessons in disease modification offered by the fields of oncology and cystic fibrosis that can be adapted to the field of neurodegeneration. Matching a biology-correcting therapy with those biologically suitable to benefit from such therapy represents the vision and mission of precision medicine, the highest level of personalized medicine. See more
Current price €217.54
Original price €228.99
Save 5%
Age Group_Uncategorizedautomatic-updateB13=Alberto J. EspayCategory1=Non-FictionCategory=MBGRCategory=MFGMCategory=MJGCategory=MJNCategory=PSANCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=In stockPrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 192 x 262mm
  • Publication Date: 28 Jun 2023
  • Publisher: Elsevier - Health Sciences Division
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780323855389

About

Dr. Alberto Espay is Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinsons disease at the University of Cincinnati. He has published over 300 peer-reviewed research articles and 8 books including Common Movement Disorders Pitfalls which received the Highly Commended BMA Medical Book Award in 2013 and Brain Fables the Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer them coauthored with Parkinson patient and advocate Benjamin Stecher selected by the Association of American Publishers for the PROSE Award honoring the best scholarly work in Neuroscience published in 2020. He has served as Chair of the Movement Disorders Section of the American Academy of Neurology Associate Editor of the Movement Disorders journal and on the Executive Committee of the Parkinson Study Group. Among other honors he has received the Cincinnati Business Couriers Health Care Hero award the Spanish Society of Neurologys Cotzias award and honorary membership in the Mexican Academy of Neurology. He currently serves as President-Elect of the Pan-American Section of the International Parkinson and Movement Disorders Society. With colleagues at the University of Cincinnati he launched the first biomarker study of aging (CCBPstudy.com) designed to match people with neurodegenerative disorders to available therapies from which they are most biologically suitable to benefit regardless of their clinical diagnoses.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept